Biodesix Company Insiders

BDSX Stock  USD 5.58  0.38  6.38%   
Slightly above 66 percent of all Biodesix's insiders are acquiring. The analysis of the overall insider sentiment regarding Biodesix suggests that a large number of insiders are confidant. Biodesix employs about 273 people. The company is managed by 21 executives with a total tenure of roughly 637 years, averaging almost 30.0 years of service per executive, having 13.0 employees per reported executive.

Insider Sentiment 66

 Mostly Buying

 
Selling
 
Buying

Latest Trades

2025-09-19Jack W SchulerAcquired 142045 @ 7.04View
2025-09-18Jack W SchulerAcquired 3056 @ 6.17View
2025-09-17Jack W SchulerAcquired 15317 @ 6.04View
2025-08-29Jack W SchulerAcquired 174418 @ 8.6View
2025-08-13Scott HuttonDisposed 188 @ 8.4View
2025-05-12Scott HuttonDisposed 94 @ 7.2View
2025-02-11Scott HuttonDisposed 4183 @ 18.4View
2024-11-20Jack W SchulerAcquired 10000 @ 23.4View
2024-11-05Matthew StrobeckAcquired 2000 @ 28View
Monitoring Biodesix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodesix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy Biodesix Stock please use our How to Invest in Biodesix guide.

Biodesix's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biodesix's future performance. Based on our forecasts, it is anticipated that Biodesix will maintain a workforce of slightly above 270 employees by February 2026.
 
Covid

Biodesix Management Team Effectiveness

The company has return on total asset (ROA) of (0.2112) % which means that it has lost $0.2112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.0255) %, meaning that it created substantial loss on money invested by shareholders. Biodesix's management efficiency ratios could be used to measure how well Biodesix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2026. Return On Capital Employed is likely to drop to -0.39 in 2026. At this time, Biodesix's Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 7.2 M in 2026, whereas Total Assets are likely to drop slightly above 89.1 M in 2026.
Common Stock Shares Outstanding is likely to rise to about 7.5 M in 2026, whereas Net Loss is likely to drop (61.8 M) in 2026.
The market capitalization of Biodesix is $47.68 Million. Biodesix retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2017-12-31
Previous Quarter
7.3 M
Current Value
7.5 M
Avarage Shares Outstanding
26.7 M
Quarterly Volatility
27.4 M
 
Covid
Some institutional investors establish a significant position in stocks such as Biodesix in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Biodesix, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Biodesix Workforce Comparison

Biodesix is rated second in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,628. Biodesix retains roughly 273 in number of employees claiming about 10% of equities under Health Care industry.

Biodesix Profit Margins

The company has Profit Margin (PM) of (0.49) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.32.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.530.7
Way Down
Slightly volatile

Biodesix Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biodesix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biodesix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biodesix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2026-03-01
18.0
18
1
 269,048 
 1,143 
2025-12-01
0.5
5
10
 944.00 
 1,244 
2025-09-01
0.9167
11
12
 3,695,141 
 52,257 
2025-06-01
1.2353
21
17
 5,508,674 
 73,994 
2025-03-01
1.0
22
22
 3,516,671 
 663,530 
2024-12-01
1.0
15
15
 662,791 
 24,641 
2024-09-01
0.375
6
16
 45,207 
 51,031 
2024-06-01
2.1429
45
21
 6,039,308 
 244,768 
2024-03-01
1.4
28
20
 2,722,041 
 426,477 
2023-12-01
0.3333
5
15
 18,836 
 24,702 
2023-09-01
0.9677
30
31
 17,029,132 
 427,956 
2023-06-01
0.95
19
20
 529,985 
 94,863 
2023-03-01
2.0556
37
18
 3,317,563 
 541,091 
2022-12-01
1.12
28
25
 24,609,990 
 133,759 
2022-09-01
0.25
4
16
 66,890 
 98,257 
2022-06-01
0.875
14
16
 4,281,506 
 98,156 
2022-03-01
13.0
26
2
 897,876 
 5,679 
2021-06-01
2.4
12
5
 218,964 
 48,932 
2020-12-01
0.5441
37
68
 12,007,530 
 56,757,851 

Biodesix Notable Stakeholders

A Biodesix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biodesix often face trade-offs trying to please all of them. Biodesix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biodesix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Heinrich DPhilFounder CTOProfile
Scott HuttonCEO PresidentProfile
Robin CowieSecretary CFOProfile
Christopher VazquezController VPProfile
James MDCoChief OfficerProfile
Matt StaufferVP SalesProfile
Dr IIIChief OfficerProfile
Ryan SiurekChief OfficerProfile
Heinrich RderFounder CTOProfile
Paul BeresfordChief OfficerProfile
Steven SpringmeyerCoChief OfficerProfile
Robert CawthornFounder EmeritusProfile
Jeffrey BojarVP AffairsProfile
Michael KammerHead RadiomicsProfile
Kieran OKaneChief OfficerProfile
Gary PestanoChief OfficerProfile
Mark DeBlockVice SalesProfile
Robbie LuntSenior MarketingProfile
Bobbi CoffinChief OfficerProfile
MD FCCPCoChief OfficerProfile
Jessica OlbrichtSenior ResourcesProfile
String symbol = request.getParameter("s");

About Biodesix Management Performance

The success or failure of an entity such as Biodesix often depends on how effective the management is. Biodesix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biodesix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biodesix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.51)(0.53)
Return On Capital Employed(0.37)(0.39)
Return On Assets(0.40)(0.42)
Return On Equity(2.36)(2.48)
Please note, the imprecision that can be found in Biodesix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biodesix. Check Biodesix's Beneish M Score to see the likelihood of Biodesix's management manipulating its earnings.

Biodesix Workforce Analysis

Traditionally, organizations such as Biodesix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biodesix within its industry.

Biodesix Manpower Efficiency

Return on Biodesix Manpower

Revenue Per Employee261.3K
Revenue Per Executive3.4M
Net Loss Per Employee157.3K
Net Loss Per Executive2M
Working Capital Per Employee92.2K
Working Capital Per Executive1.2M

Additional Tools for Biodesix Stock Analysis

When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.